Kuvatris Therapeutics Inc (PXMD) Return on Assets ROA from the third quarter of 2024 to third quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kuvatris Therapeutics Inc   (PXMD)


Kuvatris Therapeutics Inc 's ROA from the third quarter of 2024 to the third quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Kuvatris Therapeutics Inc 's ROA in the third quarter of 2024?
Kuvatris Therapeutics Inc recorded a cumulative net loss of $-14 million during 12 months ending in the third quarter of 2024, resulting in a negative return on assets (ROA) of -531.36%.

However, within the Healthcare sector 999 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2024 quarter, so far to 5022, from total ROA ranking in the second quarter of 2024 at 5083.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Total Assets Change -74.63 % -84.46 % 277.59 % 157.69 % -45.92 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -14 -18 -18 -18 -12
Return On Assets (TTM) -531.36 % -560.36 % -428.26 % -493.5 % -436.45 %
PXMD's Total Ranking # 5022 # 5083 # 5119 # 5876 # 5269
Total Assets (TTM) in million 1 1 3 6 3
Seq. Total Assets Change 2.6 % -72.36 % -49.07 % 75.67 % -37.14 %
Seq. Net Income Change - - - - -

PXMD's 5 Years Annual ROA >> Back to PXMD Management Effectiveness >> Compare PXMD ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 490
Sector # 1000
Overall # 4918

Return On Assets Statistics
High Average Low
-322.99 %
-443.03 %
-560.36 %
(Sep 30 2023)   (Jun 30 2024)



  News about Kuvatris Therapeutics Inc Return on Assets ROA

PaxMedica Steps Up to Combat Sleeping Sickness Crisis in Malawi with Emergency Supply of IV Suramin

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica Inc. (Nasdaq: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, has announced its swift response to an urgent request from the Ministry of Health (MOH) of Malawi in east Africa. The MOH seeks emergency access to the company s newly registered PAX-101 (IV suramin) to address the critical shortage of medication required to combat the life-threatening sleeping sickness crisis in the region.
Sleeping sickness, also known as Trypanosoma brucei rhodesiense or Human African trypanosomiasis (TBr HAT), is a severe disease caused by the parasite Trypanosoma brucei. It is transmitted through the bite of infected tsetse flies and primarily affects rural areas in sub-Saharan Africa. The disease causes a range of symptoms, including fever, fatigue, severe headaches, joint and muscle aches, and eventually progresses to neurological symptoms, which can be fatal if left untreated.



Financial Statements
Kuvatris Therapeutics Inc 's Assets $ 1 million PXMD's Balance sheet
Kuvatris Therapeutics Inc 's Income $ -1 million Quarterly PXMD's Income Statement
PXMD's Income by Division See PXMD's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022
FY
FY
FY
Y / Y Total Assets Change 157.69 % - - - -
Total Assets in million 6 2 0 0 0
Y / Y Net Income Change - - - - -
Net Income in million -18 -15 0 0 0
Annual Return On Assets -321.98 % -671.48 % - - -

PXMD's 5 Years Annual ROA >> Back to PXMD Management Effectiveness >> Compare PXMD ROA to its Competitors



More Return On Assets Ratios
PXMD's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PXMD's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PXMD's Competitors
Subscribers only: Roa for Kuvatris Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for PXMD's Customers

You may also want to know
PXMD's Roi PXMD's Inventory Turnover Ratio PXMD's Growth Rates PXMD's Dividend Comparisons
PXMD's Profitability Ratios PXMD's Asset Turnover Ratio PXMD's Dividend Growth
PXMD's Roe PXMD's Valuation Ratios PXMD's Financial Strength Ratios PXMD's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2024, within Healthcare Sector ROA

Date modified: 2026-06-22T14:32:45+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.